PHARMA NEWS

PHARMA NEWS :- Pharmatimes

Transgene completes randomisation in phase 2 trial of tg4050 April 13, 2026
Company expects two‑year dfs data by q1 2028
John Pinching
Bayer wins MHRA approval for Kerendia in heart failure April 13, 2026
New authorisation offers additional option for patients with lvef ≥40%
John Pinching
Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb April 9, 2026
Partnership to develop next‑generation T‑cell engagers for solid tumours
John Pinching
Kainova expands DT 7012 trial into Europe April 9, 2026
First patient dosed as DOMISOL study grows beyond Australia
John Pinching
Paul Edwards April 8, 2026
Ardena has appointed Paul Edwards as Chief People Officer
John Pinching
Leading by example April 8, 2026
A journey from community pharmacy to medical leadership
John Pinching
Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease April 7, 2026
Subcutaneous delivery shows IV‑level efficacy in moderate to severe TED
John Pinching
CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment April 7, 2026
Study expands development of the antibody into hepatocellular carcinoma
John Pinching
Dale Gordon April 2, 2026
Abselion has appointed Dale Gordon as Chair of the Board of Directors
John Pinching
Talking the talk April 2, 2026
It’s the start of a beautiful friendship, as Jess takes to the page
John Pinching

PHARMA NEWS :- Pharma Voice

HHS, industry leaders spar over drug pricing, TrumpRx and PBMs April 23, 2026
Debate about drug costs erupted among prominent healthcare figures, including Dr. Oz, Mark Cuban, Calley Means and PhRMA in Washington, D.C., but they all agreed on one thing: The system is broken.
Michael Gibney
An ‘AI scientist’ can tackle drug R&D. What does that mean for pharma? April 22, 2026
A new tool is giving researchers a “data center full of genius Ph.D. students in their pocket.”
Alexandra Pecci
Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine April 22, 2026
The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy.
Gwendolyn Wu
Lilly’s CAR-T Kelonia deal cements Big Pharma’s in vivo push April 21, 2026
The pharma giant’s second CAR-T deal this year, this one worth up to $7 billion, further solidifies what the industry sees as the future of genetic medicines.
Michael Gibney
Who is Dr. Houman Hemmati, potentially CBER’s next leader? April 20, 2026
Where the rumored frontrunner stands on key issues like vaccines and public health policy.
Kelly Bilodeau
Can an LSD candidate do for anxiety what Spravato did for depression? April 17, 2026
Definium Therapeutics is expecting late-stage data for two anxiety trials in the coming months, teeing up a potential approval.
Meagan Parrish
Roche’s DAC investment; Big Pharma’s lavish CEO bumps April 17, 2026
Roche is investing in new cancer-fighting technology, and some of Big Pharma's CEOs notched some noteworthy pay hikes.
PharmaVoice Staff
How J&J plans to hit $100B in revenue this year April 16, 2026
Johnson & Johnson leaders have laid out a plan to reach record revenue this year while opening the door to more down the road.
Michael Gibney
Will cancer drugmakers ever conquer p53? April 15, 2026
The protein is implicated in a wide swath of cancers, but harnessing it for drug R&D is still a major scientific challenge.
Kelly Bilodeau
5 notable pharma CEO pay hikes in 2025 April 14, 2026
Several of pharma’s top leaders scored large pay bumps last year, including two new chiefs who joined the “$30 million club.”
Alexandra Pecci

Transgene completes randomisation in phase 2 trial of tg4050
Company expects two‑year dfs data by q1 2028
Bayer wins MHRA approval for Kerendia in heart failure
New authorisation offers additional option for patients with lvef ≥40%
Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
Partnership to develop next‑generation T‑cell engagers for solid tumours
Kainova expands DT 7012 trial into Europe
First patient dosed as DOMISOL study grows beyond Australia
Paul Edwards
Ardena has appointed Paul Edwards as Chief People Officer
Leading by example
A journey from community pharmacy to medical leadership
Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
Subcutaneous delivery shows IV‑level efficacy in moderate to severe TED
CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
Study expands development of the antibody into hepatocellular carcinoma
Dale Gordon
Abselion has appointed Dale Gordon as Chair of the Board of Directors
Talking the talk
It’s the start of a beautiful friendship, as Jess takes to the page

GMP and Quality

Non-conformances in Pharmaceutical Laboratories

Pharma VedMay 8, 2024

Pharmaceutical quality control laboratories are the guardians of public health. Through meticulous testing of raw materials, in-process materials, and finished products, they ensure the safety and efficacy of medications. However, nonconformances can arise...